ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 117,07
-0,18%
Dow Jones
39 056,39
0,44%
DAX
18 539,49
0,28%
Brent Oil
83,77
0,25%
Bitcoin
61 074,55
-0,18%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) Actualités

INCY

Incyte (INCY)

Incyte Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INCY
DateHeureSourceTitreSymboleSociété
02/05/202414h00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
30/04/202413h00Business WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
24/04/202400h11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
24/04/202400h01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
23/04/202413h00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
11/04/202414h00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
01/04/202414h30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
29/03/202421h30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
11/03/202413h57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
11/03/202413h57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
11/03/202411h06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
11/03/202410h53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
10/03/202421h05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
10/03/202421h05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
04/03/202420h38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
04/03/202420h02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
04/03/202414h00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
29/02/202416h19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
29/02/202413h30GlobeNewswire Inc.Knight Therapeutics Announces Launch of Minjuvi® in BrazilNASDAQ:INCYIncyte Corporation
28/02/202415h11Business WireIncyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôteNASDAQ:INCYIncyte Corporation
28/02/202413h15Business WireIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hatNASDAQ:INCYIncyte Corporation
27/02/202422h08Business WireIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
16/02/202422h04Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:INCYIncyte Corporation
16/02/202418h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
13/02/202423h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
13/02/202422h03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INCYIncyte Corporation
13/02/202413h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
13/02/202413h00Business WireIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesNASDAQ:INCYIncyte Corporation
06/02/202410h08Business WireIncyte erhält exklusive weltweite Rechte für die Entwicklung und Vermarktung von Tafasitamab (Monjuvi ® )NASDAQ:INCYIncyte Corporation
06/02/202402h55Business WireIncyte obtient les droits exclusifs de développement et de commercialisation du tafasitamab (Monjuvi®) à l’échelle mondialeNASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
NYSE
MRK
Merck
EU
AI
Air Liquide
EU
VIV
Vivendi
EU
HO
Thales
EU
RNO
Renault
EU
SGO
Cie de SaintGobain
NASDAQ
MSFT
Microsoft
EU
ORA
Orange
NASDAQ
NVDA
NVIDIA
EU
ML
Michelin
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés